ArticleThe Lancet regional health. Western Pacific2026
Unravelling HCV diversity and resistance in Viet Nam: a cross-sectional analysis.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Background: Viet Nam has one of the world's most diverse hepatitis C virus (HCV) epidemics, dominated by genotype 6. Understanding pre-treatment resistance-associated substitutions (RASs) particularly in under-studied genotype 6 is important for informing resistance surveillance and supporting national HCV elimination strategies. We aimed to evaluate the landscape of viral diversity and baseline RASs relevant to currently used direct-acting antivirals (DAAs) in Viet Nam. Methods: We utilised whole-genome sequencing to analyse HCV isolates from a cohort of 1649 treatment-naïve patients enrolled in six clinical studies in Viet Nam between 2013 and 2023. The study assessed genotype and subtype distribution, associations with demographic and clinical variables, and prevalence of known and putative RASs in NS3, NS5A, and NS5B relevant to DAAs used in Viet Nam. Findings: Phylogenetic analysis revealed that genotype 6 was dominant (50.3%, 829/1649). We observed distinct geographical and demographic partitioning: genotype 2 was concentrated in the south and associated with older age and HIV co-infection, while genotype 3 was clustered in the north among younger males. Clinically relevant RASs were detected in 37.9% (617/1630) of patients, with the highest burden in NS5A region. Genotypes 2 and subtype 3b demonstrated a high prevalence of subtype-specific polymorphisms occurring at previously reported resistance-associated positions. Among genotype 6 infections, subtype 6a frequently carried L28F mutation (43.3%, 181/418), whereas subtype 6e demonstrated a low prevalence of previously reported clinical RASs. Interpretation: Viet Nam is characterised by a complex, genotype 6-predominant HCV epidemic with substantial subtype-specific baseline resistance diversity. The high prevalence of subtype-defining polymorphisms observed in several genotype 2 and subtype 3b lineages highlights the importance of continued molecular surveillance and may have implications for optimisation of DAA regimen selection and resistance monitoring strategies within highly diverse HCV populations. Funding: Wellcome Trust.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.